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Compared with traditional drug solutions or suspensions, polymeric microparticles represent a valuable
means to achieve controlled and prolonged drug delivery into joints, but still suffer from the drawback of
limited retention duration in the articular cavity. In this study, our aim was to prepare and characterize
magnetic biodegradable microparticles containing dexamethasone acetate (DXM) for intra-articular
administration. The superparamagnetic properties, which result from the encapsulation of superpara-
magnetic iron oxide nanoparticles (SPIONs), allow for microparticle retention with an external magnetic
ﬁeld, thus possibly reducing their clearance from the joint. Two molecular weights of poly(lactic-co-gly-
colic acid) (PLGA) were used, 12 and 19 kDa. The prepared batches were similar in size (around 10 lm),
inner morphology, surface morphology, charge (neutral) and superparamagnetic behaviour. The SPION
distribution in the microparticles assessed by TEM indicates a homogeneous distribution and the absence
of aggregation, an important factor for preserving superparamagnetic properties. DXM release proﬁles
were shown to be quite similar in vitro (ca. 6 days) and in vivo, using a mouse dorsal air pouch model
(ca. 5 days).
 2009 Elsevier B.V. All rights reserved.1. Introduction
The use of carriers such as liposomes, nanoparticles or micro-
particles for intra-articular administration of drugs has gained
wide acceptance over drug suspensions or solutions. The advanta-
ges of carriers lie in the fact that these delivery systems are,
depending on their characteristics, cleared less rapidly from the
joint, allowing for the active substance to be gradually released,
and avoiding side effects such as crystal-induced arthritis [1].
The ﬁeld of intra-articular-controlled drug delivery was pioneered
by Ratcliffe et al. [2], who prepared albumin microspheres that
could delay the clearance of a model drug from the joint, thus
forming the rationale for intra-articular injections of microspheres.
Moreover, the study also demonstrated that the clearance of this
type of microparticle from the joint, known to be driven by syno-
vial capillary and lymphatic transports, takes place within a fewll rights reserved.
ciences, University of Geneva,
a 4, Switzerland. Tel.: +41
toescu).days after injection. This study, with others [3,4], spurred the
search for methods offering more controlled and prolonged deliv-
ery to the joint, focusing on ways to avoid rapid clearance.
Our approach can also be included among the studies in this
ﬁeld. Speciﬁcally, the aim of our work was to prepare and charac-
terize dexamethasone acetate-containing magnetic poly(lactic-co-
glycolic acid) (PLGA) microparticles suitable for intra-articular
injection for the treatment of arthritis or osteoarthritis. The ratio-
nale for formulating magnetic microparticles by encapsulating
superparamagnetic iron oxide nanoparticles (SPIONs) into the
polymer matrix is to enhance the retention of the microparticles
in the joint with an external magnetic ﬁeld. Compared to other pa-
pers reporting on the iron oxide encapsulation into polymer micro-
particles [5–8], rather restricted in number, our article describes
the technology of co-encapsulation of iron oxide and a drug, pro-
cess only very rarely seen in other works. Furthermore, in contrast
to the encapsulation of iron oxide as oleic acid-coated SPIONs
described in other reports, which, despite a high encapsulation
content, could generate problems of toxicity, we encapsulate the
SPIONs as an aqueous suspension, by a double emulsion–solvent
evaporation method. The dose of dexamethasone that needs to
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kim et al. [9]. In a previous study [10], we optimized the formula-
tion process of magnetic PLGA microparticles in terms of
dexamethasone acetate (DXM) loading, encapsulating efﬁcacy
and magnetic retention by means of an experimental design. In
particular we have demonstrated that the magnetic retention of
this type of microparticle in a 0.8 T ﬁeld was more than 80%, mak-
ing the microparticle suitable for clinical applications.
Considering that microparticle parameters such as size, shape,
and polymer type inﬂuence the success of intra-articular local
treatment of joint inﬂammation, we have carefully chosen micro-
particle speciﬁcations based on extensive literature data. Regard-
ing particle size, small particles are easily phagocytosed, with
reported limits ranging from the nanometer range up to a few
micrometers. Howie et al. [11] reported that the macrophage re-
sponse to particles larger than 5 lm in diameter represents the
approximate upper limit for phagocytosis. Horisawa et al. [12]
used ﬂuorescently labelled PLGA nanoparticles (mean diameter
265 nm) and microparticles (mean diameter 26 lm) to evaluate
synovial phagocytosis. As expected, nanoparticles were extensively
phagocytosed and subsequently transported through the synovial
membrane within 3–7 days. In contrast, 26 lm mean diameter-
microparticles were neither phagocytosed nor transported to the
underlying synovial membrane. Furthermore, the 26 lm diameter
particles of Horisawa et al. triggered a granulation reaction with
multinuclear giant cells. This tissular reaction could have resulted
from a number of factors other than particle size, such as micropar-
ticle concentration in the articulation, polymer type or even parti-
cle shape. Concerning particle shape, Liggins et al. showed that
irregular, milled chitosan particles induced joint inﬂammation de-
spite the known articular biocompatibility of this biomaterial [13].
Because irregularly shaped microparticles are known to promote
inﬂammation in diverse tissues, round-shaped microspheres are
preferable for intra-articular delivery. Finally, with regard to the
macromolecular carrier, Ratcliffe and co-workers [14] intra-articu-
larly injected 1–10 lm microparticles made of various polymers
and showed that these materials elicited inﬂammation at different
levels: severe for poly(butyl cyanoacylate), moderate for gelatine
or poly(lactic acid) and weak for albumin. For our project, we
decided to use PLGA as a polymer matrix for the microparticles,
based on the demonstrated biocompatibility of PLGA with the
articular tissues [12,13].
Considering the factors mentioned above, we prepared mag-
netic PLGA microparticles with a mean diameter of around
10 lm for the local treatment of arthritis or osteoarthritis. The par-
ticles could possibly be maintained in the synovial space with an
external magnet, ensuring a local release of the active substance,
dexamethasone acetate. In this article, the optimized microparti-
cles will be characterized by size, surface morphology, surface
charge, SPION distribution inside the particle, magnetism, as well
as in vitro and in vivo dexamethasone release.2. Materials and methods
2.1. Materials
Poly(DL-lactide-co-glycolide) (PLGA) 75:25, inherent viscosity
0.16–0.24 dl/g, MW 19 kDa (Resomer RG 752S) and PLGA 50:50,
inherent viscosity 0.16–0.24 dl/g, MW 12 kDa (Resomer RG
502S), both of them having alkyl end groups, were provided by
Boehringer Ingelheim (Ingelheim am Rhein, Germany). Dexameth-
asone 21-acetate (DXM) was purchased from Sigma–Aldrich (Epal-
inges, Switzerland). Poly(vinyl alcohol) (PVA, Mowiol 4-88,
hydrolysis degree 88% and mean molecular weight of 26 kDa)
was a gift from Clariant GmbH (Frankfurt am Main, Germany). SPI-ONs were prepared according to the method described by Chastel-
lain and co-workers [15] and were used as an aqueous suspension,
with an iron content of 10.3 mg/mL, as assessed by atomic
absorption.
2.2. Preparation of microparticles
The preparation of the microparticles was carried out by a dou-
ble emulsion–solvent evaporation technique whereby SPIONs were
encapsulated, and by simple emulsion solvent evaporation for the
batches without SPIONs. The solvent mixture used was ethyl ace-
tate with 10% ethanol, chosen based on preliminary DXM solubility
studies using HPLC. The measured solubility in the mixture was
19 mg/mL, but decreased to 15 mg/mL upon the addition of
300 mg/mL RG 502S. From these values, we selected a DXM con-
centration of 10 mg/mL, in order to ensure proper solubilization
and avoid crystal formation. Thus, the organic phase of the emul-
sion contained 300 mg/mL of polymer and 10 mg/mL DXM in ethyl
acetate with 10% ethanol as co-solvent. Microparticles were pre-
pared by emulsifying a volume of 3.5 mL organic phase containing
0.7 mL of ferroﬂuid (10.3 mg/mL iron) with a sonicator for 10 s.
This primary emulsion was emulsiﬁed with 7 mL of 2% PVAL with
a high speed homogenizer for 1 min at 8000 rpm. The ﬁnal emul-
sion was then poured into 50 mL of 0.6% PVAL solution and stirred
for 4 h at room temperature at 500 rpm. The resulting microparti-
cles were separated by centrifugation, washed three times with
deionised water and ﬁnally freeze-dried and stored at 4 C. Using
the same method and the same technological parameters, a batch
of ‘‘blank” microparticles was prepared for each of the two poly-
mers (without DXM or SPIONs). Moreover, a batch of microparti-
cles containing only DXM and another one of microparticles
containing only SPIONs were also prepared using the two polymers
by the simple emulsion technique and double emulsion technique,
respectively (Table 1).
2.3. Scanning electron microscopy (SEM)
Scanning electron microscopy was performed on gold-coated
freeze-dried samples (Balzers SCD 004 Sputter Coater) with a JEOL
JSM-6400 microscope (JEOL Europe S.A., Croissy-sur-Seine, France)
at an accelerating voltage of 15 kV in order to determine the sur-
face characteristics of the particles. For the visualization of the
microparticle inner structure, cryo-fracturing SEM was used. Sam-
ples (1 mm3) were mounted on gold carrier plates and frozen by
plunging into liquid propane (cooled by liquid nitrogen). Under li-
quid nitrogen, the carriers were then clamped to a specimen table,
which was inserted into the cryo-unit (attached to a JEOL 6300
SEM) under a ﬂow of dry nitrogen. To retain the samples in the
fully frozen hydrated state they were kept at 120 C and the sput-
tering process was started before fracturing. Then, the samples
were fractured with a pre-cooled knife and coated with 10 nm of
gold at a total pressure of 1.7  102 mbar under pure argon gas.
After completing the coating, high vacuum was re-established
and the samples were transferred on-line to the SEM cryo stage.
The SEM stage was cooled to150 C. SEM images were taken with
an accelerating voltage of 15 kV.2.4. Particle size distribution
The particle size was determined by laser diffraction with a
Mastersizer apparatus (Malvern, Worcestershire, UK). The mean
diameter used in this article represents the volumemean diameter,
D[4; 3], D[0.1], D[0.5] and D[0.9] stand for the size of particle at
which 10%, 50% and 90% of the sample are below this size in vol-
ume or in number. In addition, the span was calculated as follows:
Table 1
Preparation of the eight batches of microparticles.
Polymer SPIONs DXM Technique Batch number
RG 502S   Simple emulsion A1
+  Double emulsion B1
 + Simple emulsion C1
+ + Double emulsion D1
RG 752S   Simple emulsion A2
+  Double emulsion B2
 + Simple emulsion C2
+ + Double emulsion D2
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ray spectroscopy (EDX)
Thin sections (40 nm) of samples embedded in epoxy resin were
cut with an ultramicrotome and placed on a copper grid covered by
a carbon ﬁlm. The sections were observed with a transmission
electron microscope Philips CM 30 at 300 kV. Chemical analyses
were performed by energy-dispersive X-ray spectroscopy.
2.6. Electron energy loss spectroscopy (EELS)
In order to determine the oxidation state of the iron in the
microparticles, electron energy loss spectroscopy was used. The
experiment was performed on the same sections that underwent
TEM and EDX with a Hitachi HF-2000 equipped with a ﬁeld emis-
sion gun operated at 200 kV. The samples were cooled to liquid
nitrogen temperature to prevent beam-induced contamination.
The EEL spectra were recorded using a Gatan 666 parallel detection
EEL spectrometer with an energy resolution of 0.5 eV and a maxi-
mum dispersion of 0.05 eV per channel.
2.7. Zeta potential
The zeta potential was measured with a Zetasizer 3000HS (Mal-
vern, Worcestershire, UK) by electrophoretic mobility on suspen-
sions of microparticles in 0.001 M NaCl with 0.1 M HCl or 0.1 M
NaOH as pH modiﬁers, and represent the average of ﬁve
measurements.
2.8. Differential scanning calorimetry (DSC)
DSC study was performedwith a DSC Seiko 220C (LabPlus, Bubi-
kon, Switzerland) in sealed aluminium pans by heating samples at
10 C/min in the 20–300 C range, cooled at 20 C and then re-
heated at 100 C. The instrument was calibrated using indium.
2.9. X-ray diffraction (XRD)
The XRD measurements, having the purpose of studying the
crystallinity of DXM and of the SPIONs inside the microparticles,
were conducted in an X-ray diffractometer (Philips PW1820) oper-
ating with Cu Ka1 and Ka2 X radiations. The scans were recorded
in the 2h range of 10 and 100.
2.10. Superconducting quantum interference device (SQUID)
The magnetization was measured in a Quantum Design MPMS-
5 SQUID (Palaiseau, France) magnetometer, using a scan length of
4 cm. We performed hysteresis loop measurements at T = 300 K, up
to 3000 Oe. We characterized the quality of the superparamagneticbehaviour from the hysteresis between the ascending and
descending branches of the magnetization vs. the applied ﬁeld plot
and from the remanent magnetization value.
2.11. Drug loading
DXM loading of batches C1, D1, C2 and D2 was measured by
HPLC after solubilization of the particles in acetonitrile. The suspen-
sion obtained after solubilization was centrifuged at 21,000 rpm in
order to separate the insoluble SPIONs (batches D1 and D2) from
the DXM-containing solution. The supernatant was analyzed using
a 100-5 C18 Nucleosil column (250/4.6, Macherey Nagel), an aceto-
nitrile: water 1:1 mobile phase, a ﬂow rate of 0.8 mL/min and
detection at 254 nm in order to assess DXM quantity.
2.12. In vitro drug release
In vitro DXM release was studied only on the batches containing
both DXM and SPIONs (D1 and D2). In practical terms, 10–15 mg of
microparticles were placed in 50 mL of 15 mM PBS at pH 7.4 with
2 mM sodium azide as a preservative and 0.5% polysorbate 80 as a
solubility enhancer. The quantity of particles was adjusted in order
to maintain sink conditions throughout the whole experiment. The
suspension was circularly shaken at 120 rpm and 37 C in a GFL-
3033 shaker (Burgwedel, Germany). At deﬁned time intervals, ali-
quots of 0.5 mL were withdrawn and centrifuged to separate
microparticles, which were returned to the release medium. Super-
natants were assayed for DXM using HPLC. The withdrawn volume
was replaced with fresh PBS. All experiments were performed in
triplicate. At the end of the experiment, microparticles were sepa-
rated, washed three times with puriﬁed water, lyophilised and
viewed under a SEM to assess for signs of degradation.
2.13. In vivo drug release
The in vivo release study was performed using a dorsal air
pouch model in mice [16–18]. C57Bl/6 mice (purchased from Har-
lan, France), aged between 8 and 10 weeks, were injected subcu-
taneously in the back with 4 mL of air, under isoﬂuorane
anaesthesia. The next day 0.5 mL of 2% sodium carmellose solu-
tion (carboxymethylcellulose sodium salt, low viscosity, Sigma–
Aldrich, Epalinges, Switzerland) was injected into the pouch in or-
der to accelerate exudative inﬂammation. Three days later, 0.5 mL
of 10 mg/mL particle suspension in PBS was injected into the
pouch. Five mice were sacriﬁced by CO2 inhalation at each time
point (1, 2, 3 and 6 days after microparticle injection). The pouch
was opened and the microparticles were withdrawn, washed
three times with puriﬁed water, lyophilised and used for the
HPLC assessment of the remaining DXM into the particles. Re-
trieved particles were also examined using a SEM to visualise
possible degradation. All experimental procedures on animals
were performed in compliance with the Swiss Federal Law on
the Protection of the Animals, according to a protocol approved
by the Swiss authorities.3. Results and discussion
3.1. Microparticle morphology
The scanning electron micrographs (Fig. 1) reveal that the
microparticles are spherical and exhibit a smooth surface without
pores or channels. Furthermore, micrographs indicate that encap-
sulation of SPIONs and/or DXM leads to an increase in microparti-
cle size. One possible explanation for this increase would be the
decrease in viscosity resulting from the presence of the internal
Fig. 1. Scanning electron photomicrographs of the RG 502S batches (A1, B1, C1, and D1) and the RG 752S batches (A2, B2, C2, and D2).
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reported by Le Ray et al. for vancomycin-encapsulating poly(e-cap-
rolactone) microparticles [19].
In order to determine the inner structure of the microparticles
and the details of their surface morphology, freeze-fracture scan-
ning electron microscopy was performed. The images presented
in Fig. 2 show that the microparticle inner structure can exhibit
different morphologies. These different types of structures result
from the fact that during the solvent evaporation and polymer
precipitation the emulsion microdroplets coalesce, creating larger
internal aqueous phase droplets [20]. The hardening of emulsion
droplets with only one inner droplet of internal aqueous phaseresults in the formation of capsule-like structures. Moreover, dur-
ing lyophilisation, the internal aqueous phase evaporates and the
capsules can collapse, appearing as deﬂated balls (Fig. 1 batch
D2). Fig. 2c shows another type of microparticle inner structure
having a few small cavities. This structure results from the hard-
ening of emulsion droplets having numerous aqueous phase
droplets. Finally, in Fig. 2a, plain microparticles, resulting from
the hardening of droplets containing no aqueous phase, are
shown at a lower magniﬁcation than the two previous examples.
These three types of internal structures are present in different
proportions in all batches prepared by the double emulsion–sol-
vent evaporation technique. Finally, images obtained with the
Fig. 2. Inner structure of the microparticles (batch D2). Different types of inner
structure are present for the microparticles of the same batch. Similar images were
recorded for all other batches prepared by the double emulsion–solvent evapora-
tion technique.
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Fig. 1, acquired at 15 kV), allow us to state with certainty that the
microparticle surface is smooth and without pores.3.2. Microparticle size distribution
Larger particles were obtained with the RG 752S polymer, due
to the higher viscosity of the 19 kDa RG 752S polymer organic solu-
tion. Moreover, as shown by SEM, particle size also increased when
DXM or SPIONs are encapsulated. The D[4; 3] percentage of in-
crease is 17% when SPIONs or DXM are encapsulated and 36%
when both substances are embedded into the RG 502S polymer
microparticles. The percentage of increase was 10%, 66%, and 12%
when SPIONs, DXM and both chemical entities, respectively, are
encapsulated into RG 752S microparticles. In general, the volume
mean diameter, D[4; 3], varies between 4.1 lm for the blank RG
502S microparticles (batch A1) to 12.6 lm for the SPION-encapsu-
lating RG 752S microparticles (batch C2). In all cases, microparticle
sizes are homogeneous with narrow and monomodal distributions
(Table 2).3.3. SPION localization into the microparticles
Fig. 3a shows the transmission electron micrograph of a cap-
sule-like microparticle having peripheral localization of the SPI-
ONs. At a higher magniﬁcation (Fig. 3b) it can be clearly
observed that no signiﬁcant nanoparticle aggregation is visible.
In order to conﬁrm the chemical nature of the nanoparticles,
EDX was performed on the circular zone as shown in Fig. 3. Addi-
tionally, a reference spectrum was acquired in a zone containing
the EPON ﬁlm without nanoparticles. The iron and oxygen peak
areas increased by approximately ﬁve- and sixfold, respectively,
compared to the reference. The data indicate that the nanoparticles
are composed of iron and oxygen. However, the exact composition
in these two elements cannot be precisely determined, both be-
cause EDX is not an accurate method to determine the light ele-
ments like oxygen or carbon and because the signal from the
nanoparticles is situated at the quantiﬁcation limit of the
apparatus.3.4. Iron oxidation state in the microparticles
The inner-shell excitation of the atoms with an electron beam
leads to characteristic edges in the electron energy loss spectrum.
The onset energies of each edge can be used to identify individual
chemical elements to study bonding and local electronic properties
of materials [21]. Fig. 4a represents the dark ﬁeld scanning trans-
mission electron micrograph of the SPIONs in the wall of a micro-
particle (visualized as white spots) which served for the
measurement of the EEL spectrum, as shown in Fig. 4b. The EEL
spectrum of the SPIONs involves the L3 and L2 edges of iron and
the ratio L3/L2 of their relative intensities can be used to quantify
the Fe3+/
P
Fe [22]. The measured ratio L3/L2 of 5.61 ± 0.07 is con-
sistent with the previously published values for Fe3+ (5.64 ± 0.10)
and excludes the signiﬁcant presence of magnetite (5.00 ± 0.09)
[23]. Therefore, the iron oxide contained in the microparticles is
in the form of maghemite.3.5. Microparticle surface charge
The magnitude of the zeta potential, which determines the
charge at the boundary of the diffuse region situated around
the Stern layer, gives an indication on the stability of a colloidal
system. The plot of the microparticle zeta potential as a function
of pH (Fig. 5) shows that all batches, independently of the pH,
have zeta potential values between 5 and 5 mV, leading to the
conclusion that microparticle suspensions would not be very sta-
ble over time. For this reason, particles were stored as a lyophi-
Table 2
The size distribution of all microparticle batches.
Batch number D[4; 3] (lm) In volume In number
D[0.1] (lm) D[0.9] (lm) Span D[0.1] (lm) D[0.9] (lm) Span
A1 4.1 2.2 6.0 0.88 1.7 4.1 1.01
B1 4.8 2.2 7.9 1.19 1.5 4.2 1.20
C1 4.8 2.1 8.3 1.32 1.4 3.5 0.96
D1 5.6 2.6 9.0 1.19 1.6 5.0 1.40
A2 7.6 2.9 13.4 1.61 1.7 5.5 1.56
B2 8.4 3.8 14.3 1.38 1.7 6.0 1.69
C2 12.6 4.9 19.4 3.21 1.6 6.4 1.75
D2 8.5 3.3 14.8 1.52 1.8 5.8 1.51
Fig. 3. (a) TEM image of microparticles (batch D2) with the dark spots of ca. 10–20 nm corresponding to the SPIONs and the circular zone delimiting the area used for EDX. (b)
Higher magniﬁcation picture of a peripheral zone showing discrete SPIONs.
Fig. 4. (a) Dark ﬁeld scanning transmission electron (DSTEM) micrograph image of a microparticle peripheral zone. The black line represents the zone in which the EEL
spectra have been recorded. (b) EEL spectrum recorded along the black line. The spectrum has been deconvoluted and the area of the two peaks measured. The largest peak
corresponds to the Fe3+ and the smaller one to Fe2+.
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of view, Fig. 5 shows that the zeta potential of the SPIONs de-
creases from positive values to negative ones when the pH in-
creases, with an isoelectric point at a pH around 7, already
reported in the literature [4]. The zeta potential of DXM crystals
was also measured as a function of pH and, as can be seen in
Fig. 5, the values remain in the negative zone regardless of the
pH. These two observations, along with the fact that blank micro-
particles do not show any zeta potential variation with the pH, al-
low us to conclude that neither DXM nor SPIONs are present at
the surface of the microparticles. Finally, in addition to the stabil-
ity problem, the surface charge of the particles represents an
important factor in predicting the in vivo degree of interaction
with the cell surface and thus the degree of microparticle uptake
by the cells.3.6. DXM physical state in the microparticles
DSC analysis of RG 752S composite microparticles (Fig. 6a), a
physical mixture of RG 752S and DXM in the same proportions
as in the microparticles (Fig. 6b), the polymer alone (Fig. 6c), and
DXM alone (Fig. 6d) were carried out to determine the physical
state of the DXM inside the particles as well as the changes in
the thermal behaviour of the components once they were formu-
lated as microparticles. Preliminarily, knowing that DXM exhibits
polymorphism, we have determined by means of IR spectroscopy
the form of the DXM used, which has been identiﬁed as Form II
(data not shown), according to Kunhert-Brandstätter et al. [24].
The DSC thermogram of the microparticles (Fig. 6a) shows a peak
at 50.5 C after a ﬁrst heating cycle, corresponding to the enthalpy
relaxation or the stress relief [25,26]. Moreover, no melting point
Fig. 5. Zeta potential of the microparticle batches, of DXM suspension and SPION
suspension as a function of the pH.
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Fig. 7. The XRD spectra of DXM and SPIONs.
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ularly dispersed or in an amorphous state in the polymer matrix.
On the thermogram of the physical mixture of polymer and DXM
the peak corresponding to the enthalpy relaxation appears at
44.1 C. On the same thermogram, the endothermic peak at
210.1 C results from the melting of DXM Form II. This is followed
by the exothermic peak corresponding to the crystallization of
Form I and the endothermic peak for the melting of the latter, at
222.4 C, accompanied by some decomposition. On the thermo-
gram of the polymer, the peak for the enthalpy relaxation appears
at 45 C. Finally, the thermogram of the DXM presents two endo-
thermic peaks, one at 217.1 C and another at 234.3 C, due to
melting of the two polymorphic forms. From these four thermo-
grams, it can be seen that the enthalpy relaxation peak is shifted
to higher temperatures in the microparticle case compared to the
polymer alone or to the physical mixture cases. This shift could
be due to the presence of DXM or SPIONs into the microparticles
that act as impurities and change the melting temperature. More-
over, the DXM melting temperature in the physical mixture is re-
duced compared to DXM alone, also resulting from the presence
of impurities (e.g. in the polymer) that contaminate the DXM, dis-
turbing its regular crystalline pattern. Furthermore, the presence of
impurities is also the cause of the broadening and the depression of
the DXM melting peak in the physical mixture of polymer and
DXM. Upon a second heating of the samples up to 100 C at the
same heating rates, the Tg of the polymer could be measured
(Fig. 6e–g). In this case we could also see a shift, notably the Tg
of the polymer inside the microparticles (40.6 C) or in the physical
mixture of polymer and DXM (40.5 C) being about 3 C higherFig. 6. DSC thermograms after a ﬁrst heating run from 20 to 300 C of the SPION- and DX
RG 752S (c), and DXM (d) and the thermograms after the second heating run, showi
microparticles (f) and of the physical mixture of RG 752S and DXM (g).than that of the polymer alone (37.9 C). This shift also results from
impurities. The same type of observations could me made for the
RG 502S polymer (results not shown).
3.7. Crystalline structure determination
The crystallinity of the DXM alone, of the lyophilised SPIONs,
and of the complete microparticles (batches D1 and D2) was stud-
ied by XRD. In Fig. 7, the XRD spectrum of pure DXM indicates a
crystalline structure in the orthorhombic system. For the SPION
sample, we obtained a pattern showing ﬁve characteristic peaks
of the spinel structure of either maghemite or magnetite, in accor-
dance with the previously published results [5]. In contrast, the
spectra of both microparticle batches (not shown) do not display
any crystalline peaks, most probably because the amounts of SPI-
ONs and DXM are below the detection limits of the method.
3.8. Magnetic properties
Using SQUID, we measured the magnetic properties of the com-
posite microparticles of batches D1 and D2, which have a SPION
content of 0.9%, and compared them with dried SPIONs as well
as with a mixture of polymer and 0.9% SPIONs. The magnetization
curves present negligible hysteresis loops, demonstrating that the
iron oxide nanoparticles present in the samples have a superpara-
magnetic behaviour. The normalized curves to the SPION content
in each sample superpose, leading to very similar saturation mag-
netizations. This indicates that the process of encapsulation does
not change the magnetic properties of the SPIONs. This result is
fundamental to future clinical applications, as it shows both that
microparticles will not present remanent magnetization upon the
suppression of the magnetic ﬁeld and that the effective surface of
SPIONs will not be diminished due to aggregation, in accordanceM-containing RG 752S microparticles (a), physical mixture of RG 752S and DXM (b),
ng the glass transition of RG 752S alone (e), of the SPION- and DXM-containing
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Fig. 9. In vitro drug release pattern of the batches D1 (d) and D2 (h). Error bars
indicate standard error of the mean. Plain lines represent the ﬁrst order kinetics
ﬁtting.
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tion saturation of the lyophilized SPIONs of 51 emu/g represents
the highest value among the studied samples. This result is compa-
rable with the values obtained by other research teams. For exam-
ple, Hamoudeh and co-workers [4] reported values of 70 emu/g for
magnetite prepared by the co-precipitation method. Furthermore,
the value of the saturation magnetization for a mixture of RG
752S and lyophilized SPIONs was of 50.7 emu/g and of 45 emu/g
for the batch D1 and of 46.7 emu/g for the batch D2 (Fig. 8). All
these values were calculated for a magnetic ﬁeld of 0.3 T, which
is typically the value of the magnetic ﬁeld which should be clini-
cally used.
3.9. In vitro DXM release
In vitro release studies of batches D1 and D2 (drug loading of
2.3% and 2.5%, respectively, representing loading efﬁcacy of more
than 75%) were conducted over 8 days. The release proﬁles
(Fig. 9) demonstrate that the two batches present a sustained re-
lease during the studied period. It is important to note that micro-
particles of the batch D1 prepared with RG 502S completely
released the active substance, while the microparticles prepared
with RG 752S released only 80% of the active substance during
the 8 days of the experiment. This phenomenon could be due to
the fact that, in the RG 752S microparticles (batch D2), DXM is
more strongly associated to the polymer chains through hydropho-
bic interactions than in the RG 502S microparticles, due to a more
important hydrophobicity of the ﬁrst polymer compared to the
second one. The curves were ﬁtted to the semi-empirical model:
Mt ¼ M1ð1 expktÞ ð2Þ
where Mt and M1 are the cumulative amount of drug released at
time t and inﬁnite time, k is a rate constant depending on the char-
acteristics of the releasing system. For times longer than 3 days, the
release rate slows to zero, indicating the end of the release process.
The calculated half-lives corresponding to the two batches were
quite similar, 0.8 days for batch D1 and 0.6 days for batch D2, with
values for the rate constants of 0.9 days1 and 1.2 days1, respec-
tively. In both cases, the correlation coefﬁcient was higher than
0.989.
Moreover, the molecular weight of the particles was deter-
mined by GPC after 21 days of in vitro release in order to test
whether there is a diminution of the polymer molecular weight.-0.30
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Fig. 8. Magnetograms of microparticle batches D1 and D2, of the SPIONs and of the
physical mixture of SPIONs and polymer.The obtained results demonstrate that the molecular weight re-
mains constant for the duration of the experiment, proving that
the DXM release process is mainly driven by diffusion. The fact that
the polymer molecular weight does not change is consistent with
SEM observations on the microparticles after 21 days of in vitro re-
lease (Fig. 11a and b). Microparticles in these images do not show
signs of severe mechanical degradation, but only of slight surface
erosion.
3.10. In vivo DXM release
The in vivo release of the encapsulated DXMwas studied using a
dorsal air pouch model in mice, generally used to mimic inﬂamma-
tory conditions [18,27]. The purpose of this experiment was to as-
sess how DXM is released from the microparticles in the presence
of biological ﬂuids and under inﬂammatory conditions. Collville-
Nash and Lawrence [27] state that the maximal inﬂammatory re-
sponse develops after a 7-day period. In our case, the inﬂammatory
reaction was weak, due to the fact that we injected the micropar-
ticles only 4 days after the pouch formation.
The release proﬁles of the two investigated batches (Fig. 10)
demonstrate that DXM is released from both batches in about 5–
6 days. By ﬁtting the curves to the same model as for the in vitro
study, the release constants and the half-lives could be calculated.
The correlation coefﬁcient was higher than 0.995, showing that the
mathematical model ﬁtted the two curves well. For the batch D1,
the release rate constant, k, had a value of 0.5 days1 and the
half-life is 1.2 days, while for the batch D2 the release constant
was 0.3 days1 and the half-life was 2.7 days. These values show
that the DXM release from the RG 752S composite microparticles
was slower than from RG 502S composite microparticles, possibly
due to a tighter polymer network in the case of more hydrophobic
RG 752S polymer. Compared to the in vitro DXM release, the in vivo
release was characterized by smaller release constants, and hence
by larger half-lives, i.e. 1.5 and 4.3 times larger for batches D1 and
D2, respectively. This difference could result from the high viscos-
ity of environment in the pouch, due to both the presence of the
carboxymethylcellulose solution and the very small quantity of
exudate. Otherwise, the release proﬁles of the two batches have
similar tendencies in vitro and in vivo. In both cases, the batch D1
released the active substance more rapidly than the batch D2
did. In order to mathematically assess whether the in vitro and
in vivo release proﬁles for batches D1 and D2, respectively, were
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Fig. 10. In vivo drug release pattern of batches D1 (d) and D2 (h). Plain lines
represent the ﬁrst order kinetics ﬁtting. Error bars indicate standard error of the
mean.
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calculated [28].
f1 ¼
P jRt  Tt jP
Rt
 100 ð3Þ
f2 ¼ 50 log 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ 1n
PðRt  TtÞ2
q  100
2
64
3
75 ð4Þ
where n is the number of points in the dissolution proﬁle, Rt is the
percent dissolved for the reference standard at each time period and
Tt is the percent dissolved for the test product at the same time per-Fig. 11. Scanning electron microscopy images of microparticles of batches D1 and D2 a
release (c and d, respectively).iod, and log is logarithm base 10. For equivalency, the f1-value
should be close to 0 (generally less than 15) and the f2-value should
be close to 100 (generally with values greater than 50). In our case,
by comparing the in vitro and in vivo curves for batch D1 we ob-
tained a value of 7 for f1 and of 57 for f2, while for batch D2 the val-
ues were 28 and 36, respectively, for f1 and f2. These results prove
that the in vitro and in vivo curves are similar in the case of batch
D1 and that they are different in the case of batch D2, certainly
due to the incomplete DXM release, in the latter case.
At the end of the experiment, microparticles were analyzed by
SEM (Fig. 11c and d). The images show that the microparticles
are only slightly eroded, proving that DXM is released by diffusion
as in the case of the in vitro release. This result is also demonstrated
by the fact that the molecular weight of the microparticles, as-
sessed by GPC, does not change throughout the duration of the
experiment. This can be expected, taking into consideration the
fact that the acidic medium present in the exudate should degrade
the polymer. However, the time of the experiment is probably too
short for the hydrolysis of the polymer chains. Nevertheless, judg-
ing on the visual characteristics of the microparticle in Fig. 11, their
rough surfaces may anticipate some signs of degradation that were
not detected by gas chromatography.
In conclusion, we prepared magnetic RG 752S and RG 502S
microparticles containing dexamethasone acetate for the intra-
articular treatment of inﬂammatory diseases, such as arthritis.
The encapsulation process did not affect the magnetic properties
of SPIONs or their oxidation state. Moreover, DXM and SPIONs
were completely embedded into the microparticles, as demon-
strated by the zeta potential. The DXM microparticle loading com-
plies with the necessary dose that can be administered into the
articulation, which is of 1.2 mg/kg in rats or mice [9]. Complete
microparticles made of both polymer types comply with the
requirements for the intra-articular administering in terms of
shape and size. Furthermore, in a previous article we have demon-
strated that this type of microparticles have in vitro adequatefter 21-day in vitro drug release (a and b, respectively) and after 6-day in vivo drug
538 N. Butoescu et al. / European Journal of Pharmaceutics and Biopharmaceutics 72 (2009) 529–538magnetic retention under the action of an external magnetic ﬁeld.
The in vitro and in vivo release patterns show similarity in terms of
DXM release in the case of batches prepared with RG 502S poly-
mer. An important aspect is that the in vivo release was performed
in an inﬂammatory environment, such as in the case of arthritis,
giving us an insight into the microparticle behaviour in the joint.
As the physical characterization of the microparticles is done, stud-
ies of the interaction between the microparticles and the synovial
cells are on going [29]. From the clinical point of view, the micro-
particles are being tested for their efﬁcacy in a mouse model of
antigen-induced arthritis and their retention in the joint will be
studied in the absence or in the presence of an external magnet.
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